Heterogeneity in RAG 1/2 Deficiency: 35 Cases From A Single Center.

Karaatmaca B., Cagdas D., Esenboga S., Erman B., Tan Ç., Ozgur T. T., ...Daha Fazla

Clinical and experimental immunology, cilt.215, ss.160-176, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 215
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1093/cei/uxad110
  • Dergi Adı: Clinical and experimental immunology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, Veterinary Science Database
  • Sayfa Sayıları: ss.160-176
  • Anahtar Kelimeler: autoimmunity, erythroderma, Omenn syndrome, RAG1/2, severe combined immunodeficiency, vasculitis
  • Erciyes Üniversitesi Adresli: Evet

Özet

Recombination activating genes (RAG)1 and RAG2 deficiency leads to combined T/B-cell deficiency with varying clinical presentations. This study aimed to define the clinical/laboratory spectrum of RAG1 and RAG2 deficiency. We retrospectively reviewed the clinical/laboratory data of 35 patients, grouped them as severe combined immunodeficiency (SCID), Omenn syndrome (OS), and delayed-onset combined immunodeficiency (CID) and reported nine novel mutations. The male/female ratio was 23/12. Median age of clinical manifestations was 1 months (mo) (0.5-2), 2 mo (1.25-5), and 14 mo (3.63-27), age at diagnosis was 4 mo (3-6), 4.5 mo (2.5-9.75), and 27 mo (14.5-70) in SCID (n = 25; 71.4%), OS (n = 5; 14.3%), and CID (n = 5; 14.3%) patients, respectively. Common clinical manifestations were recurrent sinopulmonary infections 82.9%, oral moniliasis 62.9%, diarrhea 51.4%, and eczema/dermatitis 42.9%. Autoimmune features were present in 31.4% of the patients; 80% were in CID patients. Lymphopenia was present in 92% of SCID, 80% of OS, and 80% of CID patients. All SCID and CID patients had low T (CD3, CD4, and CD8), low B, and increased NK cell numbers. Twenty-eight patients underwent hematopoietic stem cell transplantation (HSCT), whereas seven patients died before HSCT. Median age at HSCT was 7 mo (4-13.5). Survival differed in groups; maximum in SCID patients who had an HLA-matched family donor, minimum in OS. Totally 19 (54.3%) patients survived. Early molecular genetic studies will give both individualized therapy options, and a survival advantage because of timely diagnosis and treatment. Further improvement in therapeutic outcomes will be possible if clinicians gain time for HSCT. The recombination activating genes (RAG) are key players for T- and B-cell development and functions. Multifarious clinical presentations have been defined as patients with RAG deficiency. Early diagnosis, effective treatment, and early hematopoietic stem cell transplantation will increase the patients' chances of survival, especially for late-onset forms. Graphical Abstract